{"efta_number": "EFTA01140225", "page_count": 14, "url": "https://epstein-data.com/EFTA01140225", "pdf_url": "https://epstein-data.com/pdf/EFTA01140225.pdf", "pages": [{"efta_number": "EFTA01140225", "page_number": 0, "text_content": "February 10, 2014 \nHi Jeffrey, \nThanks for taking time out of your schedule to talk on the phone and sorry for the delay in \ngetting you this invoice. I enjoyed discussing what we can potentially do on the research side \nwith the samples you've already submitted through the PGP. \nYou're probably inundated with proposals on a regular basis - so, to recap some of the general \npoints we discussed: \nI. George Church recommended me to you through your participation in the PGP and I \nhelped with sample collection and consenting through that study. \n2. You have a math background and a long history of supporting the sciences. My \nimpression is your interests could be considered self-discovery using the latest in \ngenomics tools: including a) sequencing, b) data analyses and storage, and c) genomic \nand functional manipulation of your own iPS and other cell lines. The PGP was supposed \nto facilitate all these pursuits. \n3. To the best of my knowledge, work on your samples are on an indefinite hold with the \npgp. Meanwhile, my own involvement with the PGP has weaned off in order to pursue \nmy own genomics research study at MGH that would be decidedly more: \na) Clinical:, obviously as a physician this is an important aspect for me but, perhaps even \nmore importantly, the recent ACMG recommendations (see attached) make it obligatory \nfor clinicians to report back incidental findings on these genes - even when sequencing \nwas done on a healthy relative to diagnose a family member with a mutation in a different \ngene(s). \nSince there's no intrinsic reason to treat the genetic results of a healthy patient getting \nsequenced for clinical reasons (eg, a sick family member) differently from a healthy \nparticipant in a clinical genomic research study, researchers will need to strongly \nconsider returning these results in a responsible way that helps steer research subjects \ntoward appropriate medical management when indicated by worrisome results (especially \nwhen occurring in the 56 \n... [truncated, 2266 chars — for the full page use /api/corpus/document/EFTA01140225/0 or ?id=EFTA01140225&page=0]", "char_count": 2266}, {"efta_number": "EFTA01140225", "page_number": 1, "text_content": "The PGP is not a clinical study (like mine will be). Their focus is primarily on creating a large \ngenomic database that could be publicly accessed to further genomics research. This is an \nimportant endeavor but for my interests and personal mission, it's restrictive to patients who are \neither (a) not interested in making their data public or (b) who are unable to properly consent to \nthis on their own (eg, due to mental retardation). So, in general, here are the areas where my \nstudy diverges from the pgp. My study focuses on improving access and the medical utililty of \nan individual's genomic data — specifically in: \nGenetics patients: maximize access and utility of next generation sequencing (ngs) in \nour MGH, as well as offsite, genetics patients most likely to benefit from it -\nregardless of their finances. (Jeffrey, sadly, ngs at MGH right now is difficult to \nobtain for patients without private insurance because of reimbursement issues. This \nisn't unique to MGH but a common issue right now across health care systems. For \nearly technologies like this one, insurers are very arbitrary about what gets \nreimbursed. And most patients can't afford to pay for this out of pocket (even when \nthe genomic test could benefit their child and the cost is only —$1000 per sample). \nii) \nGeneral public: Determine the number of healthy individuals in the general \npopulation needed to be screened with exome sequencing before 1 person has a \nsignificant medical benefit. And, maximize that clinical utility by refining the DNA \nsequencing and analysis pipeline over time. \nb) Private: I continue to be fully supportive of George's PGP efforts but he'll be the first to \nadmit that joining a public study is not for everyone. It's for the minority of people who \nare willing to take this privacy risk in the interests of science. In the case of my pediatric \npatients (which is a large proportion of any medical genetics practice), this was a non-\nstarter. Not surprisingly, the pgp doe\n... [truncated, 2953 chars — for the full page use /api/corpus/document/EFTA01140225/1 or ?id=EFTA01140225&page=1]", "char_count": 2953}, {"efta_number": "EFTA01140225", "page_number": 2, "text_content": "more data on genetic variants and improved software are available for genome re-\ninterpretation.) \nIn contrast to the pgp, my study will start with infrastructure that safeguards privacy and \nwill be focused on increasing the security/privacy of study participant data with genomic \nencryption software that are more stringent than current HIPAA regulations. Initially we \nwill try out existing software and over time (with appropriate bioinformatic support) \nimprove encryption with our own proprietary software. \n4. We discussed this point over the phone but just so you have it in an email. Work on your \nsamples, outside the pgp, can really only legitimately continue in one of 2 ways: \na) Through a clinic, or \nb) Through an IRB approved human research protocol \nI have and continue to order clinical exomes on my sickest patients suspected of severe genetic \ndisease (often these are critically ill neonates). (See attached exome paper for examples of how \nngs has helped in these situations.) Insurers typically reimburse in these extreme cases. I have \nalso had private patients with personal or family history of known or suspected genetic disease in \nwhom we ordered ngs that they paid for out of pocket. \nIn your case though, although we could stretch things a little and say \"we're doing your genome \nexploration within the clinic\", the cellular work will fall way outside of anything you would do \nin a normal clinical setting — even if you did have a serious genetic disorder. \nFurthermore, going through the clinic and doing this as my patient also obligates us to have \ndocumentation in your medical record of all encounters as well as some record of your genomic \ndata. (Raising again the issue of privacy.) \nFor all these reasons, my recommendation is to do all this work through the research route. \n(Anyone working in this space would agree with this.) \n5. Assuming we're going the research route as we discussed, I'll need to get you enrolled in \nmy study and have your samples m\n... [truncated, 2788 chars — for the full page use /api/corpus/document/EFTA01140225/2 or ?id=EFTA01140225&page=2]", "char_count": 2788}, {"efta_number": "EFTA01140225", "page_number": 3, "text_content": "I still have to submit the rest of my research protocol for approval by MGH. I wanted to \nget your feedback on the invoice and include whatever infrastructure you're willing to \nprovide though before submitting my proposal. Not surprisingly, the more infrastructure \nand funding I can cite, the more likely my proposal will get approved. If it's approved, \nthen you, myself, and the YPO Austin members (who've already enrolled) will be \ncompleting the newly approved consent form and proceed with the research. (This will \nnot require another online exam or be as onerous as the pgp enrollment.) \nThe timeline from my submitting the application is - hopefully in the next 1-2 weeks -\nafter hearing your input on this invoice. The time from MGH receiving the application to \nfinal approval is around 5 weeks if they have no major issues with the proposal. \n6. To put this work in perspective, the YPO Houston chapter collaborated with Baylor \nCollege of Medicine to produce the attached paper that I mentioned over the phone. They \ndid \"individualized\" analyses based on personal and family medical history. \nUnfortunately their paper was submitted to the journal just before the ACMG \nrecommendations came out this past summer. So our work (the YPO Austin chapter / \nHarvard Med / MGH collaboration) will have the advantage of being able to uniformly \nlook across the same 56 genes among all these study participants. This work should lead \nto data that helps determine the utility of ngs when medically screening the general \npopulation — the main focus of my lab. \nThe numbers may bounce around a bit at first — but, as more and more people are \nscreened, we'll get a better handle on the \"number needed to screen\" before a medical \nbenefit is seen. Over time, this number should decrease as our medical knowledge and \nutility of the genomic data increases. At some point, this type of screening should be \nreimbursed by insurers for everyone once the cost of sequencing is cost efficient and \nclin\n... [truncated, 3031 chars — for the full page use /api/corpus/document/EFTA01140225/3 or ?id=EFTA01140225&page=3]", "char_count": 3031}, {"efta_number": "EFTA01140225", "page_number": 4, "text_content": "to sequence so we can answer questions like: \"how is the dna sequence (and eventually ma when \nwe're further along) different between different cell lines (especially your adult stem cells once \nthey're available)?\" and \"how different do they get with every cell passage?\". Even more \ninteresting, \"how can we correct mutations in cell culture?\", and further down the road (year 3?) \n\"how can we efficiently and safely propagate these corrections in vivo?\". \nSo, to do a really in-depth genomic analysis on 1 person across cell lines in Jan 2014 with the \nlatest and greatest (see links to vendors below), you are, by necessity, purchasing a system that \ncan do the same for typically 100 or more samples anyway. (Variant analyses systems that only \nanalyze 1 genome are few and tend to be low quality.) \nJeffrey, please keep the following confidential if you don't mind since I haven't even shared my \ndetailed research plans with the chief of my genetics division yet since I don't want to get \n\"scooped\" on the idea before I have the funding needed to implement it. \nIn order to maximize medical utility and accessibility to ngs in the next 1-5 years, I believe the \ntype of infrastructure I'm proposing will need to become commonplace (or, alternatively, we'll \nneed to be the group practically providing the service for everyone!). What I'm proposing is \ninfrastructure that combines 3 cutting edge areas of medicine today with untapped potential: \na) Genomic medicine \nb) Telemedicine \nc) Concierge medicine \nRoughly the plan is: \na) Sample collection: at a minimum: noninvasive, self collected, saliva sample from study \nparticipant after telephone or videoconferenced remote enrollment. \nb) Samples may have a variety of investigations done (yours for example) but, at a \nminimum, all samples will have exomes sequenced (currently these research exomes can \nbe as low as $1000 each; you will have this plus a whole genome (about $5000) through \nIllumina; see below). \nc) All samples will go t\n... [truncated, 2821 chars — for the full page use /api/corpus/document/EFTA01140225/4 or ?id=EFTA01140225&page=4]", "char_count": 2821}, {"efta_number": "EFTA01140225", "page_number": 5, "text_content": "any time of course. It is medical advice they would never have gotten without participating in \nthe research aileron. \nAfter they get sequenced and get their exome results back, all participants will then have the \noption of: \na) Having their data and samples destroyed with the option of receiving their own copy of \nthe data, OR, \nb) Continuing in the study. The benefits of this include: ongoing research on samples \nincluding sequencing, re-analyses (at least annually, as knowledge evolves and the acmg \nlist grows over time), and back up storage of data. (I'm guessing you would be in this \ncategory if you participated. Would not make sense to me to invest in this infrastructure \nand not personally make use of it for yourself (even family, friends, loved ones) over the \nlong term.) \nThis would make it the most participant-friendly genomics study I'm aware of in terms of the \nflexibility and options study subjects are given after return of data. I truly believe this is the \ndirection these types of studies should be moving towards. \nI don't offer a \"go public\" option in my study. But any participant in the study is welcome to get \na copy of their own data - which they can make public on their own if they choose to do so \n(through the pgp or other similar efforts). \n8. Let's now break this down into various tasks and where the work will be done which will \nbe what dictates the invoice/budget for this study. I've named my study the \"Virtual \nGenomics Clinic\" or MGH VGC Study. The YPO data (which will also include your \nand my data) will be the \"pilot\" portion of the study that generates preliminary data \nnecessary for publications and more long term NIH funding. I expect a total of 80-100 \npeople enrolled in this early pilot phase of the study. If all goes well, data analysis on this \ngroup should be completed by end of May this year. \nThis is a first pass on your invoice broke down into categories of work and expense and where \nthe work will be done with explanations. \n... [truncated, 3005 chars — for the full page use /api/corpus/document/EFTA01140225/5 or ?id=EFTA01140225&page=5]", "char_count": 3005}, {"efta_number": "EFTA01140225", "page_number": 6, "text_content": "al Whole genome through Illumina: Your best clinical wgs option today: about $5000 \n2I ) Ambry research exome: will run you $1000 includes research exome and some \nanalysis from ambry; you will also get a compressed copy of your exome on memory \nstick through an arrangement we have with them. (This is what the ypo folks will \nhave done.) \ngl Complete Genommics/BGI: I would say (a) and (b) above should definitely be done \ngiven your resources and interests. (c) is optional but it would be nice to check \nconcordance with Illumina's data. Not enough groups have done this and it would be \ngreat to include this data in a publication. There really isn't enough of this type of \nvalidation in the medical literature. (This is partly because CGI does their sequencing \nas a service. And their proprietary instrument is \"black box\".) I don't have a number \nfrom them yet. But I don't think it will be more than $5000 for a whole genome. \n2. Raw data analysis and storage: What I'm envisioning for you and other study VGC \nparticipants is a dedicated room at MGH's Center for Human Genomics Research Center \nthat houses our genomic servers and doubles as a mini-exam and consultation room \nwhere results are returned either in person (if they happen to be in Boston) or via \nvideolink. \nI divide this into 2 main platforms: \na) onsite servers (there are 3 commercial vendors whose products I think are worth \npurchasing and assessing; each of these are loaded up with their own proprietary genomic \nanalyses software), AND \nb) genomic analyses software suites: 6 of these worth pursuing in my opinion. There are \nmore but the functionality starts to either overlap with these other 6 (or I don't trust the \nscience from the people putting out the product so I didn't bother listing it). \n3. individualized cellular and functional studies of your own cells (including adult stem \ncell generation and genomic manipulation/engineering of personal cells): We should \nbe able to get your fibroblasts differe\n... [truncated, 2787 chars — for the full page use /api/corpus/document/EFTA01140225/6 or ?id=EFTA01140225&page=6]", "char_count": 2787}, {"efta_number": "EFTA01140225", "page_number": 7, "text_content": "with Gerry, I do know he is worried about the actual manpower — the funding for \ntheir postdoc doing the actual cell cultures (not just yours). \nI personally know the postdoc in his lab doing the iPS cell (induced pluripotent cell or \nadult stem cell) work and she's excellent but her research funding has dried up and \nBerry lab really wants to keep her. I promised I would ask you if this was something \nyou'd be willing to support. \nYou should know that this isn't an expense you would have through a commercial \nvendor. Under normal circumstances, I also think it's a little unreasonable to ask you \nto cover the salary of the person working on your cells. \nStill, if you were willing, they are only asking for 2 years salary — which would also \nsupport her as she completed biochemical genetics training. And you would of course \nget regular updates on what was happening with your cells and she would have the \ndevoted time to keep a variety of studies going on your cells (guided by your \nsequence data). Her salary would be: $50-60k/yr X2 years. \n4. Indirect costs at HMS, MGH, and Boston Childrens: I'm sure you're familiar with \nthis next category of cost. It's one I still have a hard time justifying — not in principle but \nbecause of the large proportion that gets taken out from a total budget. I'm referring to \nthe ridiculous 60-70% \"indirect costs\" HMS, MGH, Childrens' Hospital, and any \nacademic center routinely takes out of research grants. There are mechanisms for \navoiding this with private grants like yours though and we'll pursue this. (le, bringing the \nmoney into a large research pool with the understanding that your money is specifically \nused for our genomic study (MGH VGC) is one way of doing this.) \nIn previous conversations, I did mention doing any work for you pro bono but I've been \ntold MGH/CHB/HMS will want my research effort appropriately covered for the \nappropriate %effort I devote on any grants I accept (which allows the respective \ninstitutions to p\n... [truncated, 2524 chars — for the full page use /api/corpus/document/EFTA01140225/7 or ?id=EFTA01140225&page=7]", "char_count": 2524}, {"efta_number": "EFTA01140225", "page_number": 8, "text_content": "H. \nAnalysis suites / private, restricted access MGH VGC genomics server room \nnext door to an exam room and office. \n= $190k/yr for personnel (see below) + MGH indirect costs for the space rental (to be \ndetermined) + server costs X3 (to be determined) + analyses software costs X 6 (to be \ndetermined) \nI. MGH indirect costs: Not sure what this will be. I want this to be zero — and \nthis may be possible. Indirect costs do include space rental though and that \ncost will remain so I'll look into what space for this work will run us for 1-3 \nyears. \nIdeally, our space will be rented within MGH for this research project and \ninclude: \n1 server room \n1 study office \n1 exam room \nYour support could provide the bridge funding needed for 1-3 years until other sources \n(NIH grants, etc.) can pick up expenses after we publish our initial findings and our effort \ngets on the map. \n2. Personnel: to really do this right and keep things on track, a few hires would \nreally make this effort a reality: \na) A bioinformatician:  I think we can get away with part-time help here: $301Uyear for \n<50% effort to insure IT systems are running smoothly and communicating with each \nother; as we are further along this person will potentially build out proprietary, \ninhouse analyses tools that are an improvement and hybrid version of what we \nevaluated in year 1 (and found most useful). \nb) Genetic counselor: this person will serve as our study coordinator and help with pre-\nand post-test counseling. He/she will also help me with clinical duties as \nresponsibilities increase on the research you would be supporting. Full time: $60k/yr. \nc) My own effort: 2 days/week specifically for this research (in realty my effort will be \nmore than 2 days/week). Given a $250K/yr base salary, this would be $100k/yr for \nme OR 40% effort. (What proportion of this $100K/yr would be going through MGH \nand what will be going through Boston Childrens Hospital would still need to be \ndetermined.) \n3. Servers:  Thes\n... [truncated, 2239 chars — for the full page use /api/corpus/document/EFTA01140225/8 or ?id=EFTA01140225&page=8]", "char_count": 2239}, {"efta_number": "EFTA01140225", "page_number": 9, "text_content": "Genomatix: htto://www.genomatix.de/solutions/genomatix-minine-\nstation.html \n4. Software suite vendors: These won't be as bad costwise — but there are 6 of \nthese I would get. Some of these have free versions but those versions lack a \nlot enough bells and whistles to really limit utility (probably why it's free) and \ncan't be used on more than a few genomes. I would purchase and evaluate the \npremium versions of these 6. \nft1 Cartagena: httplAvww.cartagenia.com/ \nk) DNA nexus: https://www.dnanexus.com/ \nGeneTalk: http://www.gene-talk.de/ \nAppistry: http://www.appistry.com/ \nNextCODE Health: http://www.nextcode.com/ \nBC Platforms: http://www.bcplatforms.com/ \n5. Functional studies, stem cell, and other cellular work:  This will be happening \nat Boston Childrens Hospital. And I've already discussed it with my old \nmentor, Gerry Berry, and he agrees to it. \n= $ISK + 60K = $75k/yr \nCost for reagents and other essentials: $ 15K for transformation of your \nfibros to iPS cell lines \nit) Obviously, you went with a commercial vendor through a commercial \nvendor, the work could be done without you funding a postdoc at Boston \nChildrens. That said, if you were able to fund this PhD (and way over-\nqualified tech), she would be able to fund her own a biochemical training \nwhile working on your cells as part of her required research work. The lab \nwould be indebted to you and I think you would get very good service and \nresearch on your cells doing this if it's possible. (The Berry lab protocols \noriginate from George Daley's lab — arguably the foremost authority on \nadult stem cells. Daley lab is also where George Church lab got their iPS \nprotocols.) Her salary = $60K/yr (X 2 yrs so she can complete her \ntraining.) \nEverything I've described above pertains mainly to year 1 of our MGH VGC project. Much of \nthese total costs are paid upfront too. (eg, the sequencing of cells can occur at a slower pace after \nyour exome and wgs x2 is done; and servers are a year 1 purchase). \nIf \n... [truncated, 2469 chars — for the full page use /api/corpus/document/EFTA01140225/9 or ?id=EFTA01140225&page=9]", "char_count": 2469}, {"efta_number": "EFTA01140225", "page_number": 10, "text_content": "recent advances in instrumentation that keeps this from sounding crazy and actually \nimplementable — on a desktop sequencer. \nSee: \nhttp://www.illumina.com/systems/nextseq-sequencer.ilmn \nIt might sound aggressive but with adequate funding it's very much within reach. The timeline \nwould be: \nI. Year 1(20141: Offsite sequencing; onsite genomic data storage and analysis; iPS cell line \ngeneration. \nFirst half of 2014. We nail down the analysis and storage of the sequencing data \ngenerated on you and participating YPO members (Austin chapter; I have around 80 \nenrolled right now). By June 2014, the first wave of initial analysis and individual return \nof results to all participants is completed (completing our pilot phase). Bills are paid for \nspace and essential personnel. \nSecond half of 2014 (July-Dec): Publish prelim data. Increase enrollment numbers. \nApply for grants with prelim data. \n2. Year 2 (2015): Early 2015: 2nd data release. Trim down analyses tools and servers to \nthose 1 or 2 with the best functionality and UI. Begin work on inhouse server \nconstruction, and proprietary analysis and genomic visualization software. Improve \nvideoconferencing capabilities and subject phenotyping. Start to build inhouse \ncapabilities to remotely collect EKG, EEG, sleep study, and other real time medical data. \nWith iPS cells available from year 1 (at this point, Jeffrey, you may only be 1 of 6 people \nI currently have iPS cells on so you can expect extensive studies on them) begin work \ndifferentiating into neurons and other cell lines. Collaborate with the Wyss so we can do \n\"organ on a chip\" experiments. Begin genomic engineering using CRISPR and other \ntechnologies to correct mutations in vivo with model organisms. Begin using zebrafish \nfor these studies. (Jeffrey, this is an inexpensive yet very effective animal model. Initial \ninvestment for a fully functional zebrafish lab is only around $15K/yr.) Begin RNA \nanalyses (transcriptomes) on some VGC subjects as resourc\n... [truncated, 2512 chars — for the full page use /api/corpus/document/EFTA01140225/10 or ?id=EFTA01140225&page=10]", "char_count": 2512}, {"efta_number": "EFTA01140225", "page_number": 11, "text_content": "My thinking was some of this robot's functionality can be achieved with a simple \nvideoconferencing hookup — albeit without the diagnostic tools. The $4K/month price tag \nto lease is steep but I'm sure we can get a better deal on it (especially citing our study and \nthe institution we would be conducting research at). Cost aside, I do think this is \nsomething our sick MGH kids would really enjoy (interacting with a robot!) and \nconsulting with remote experts is something we regularly do with our genetics patients. If \nit's not already obvious, doing my genetic patient rounds with this robot is clearly the \nmost optional item on the invoice. It is also the most expensive item on the invoice with \nthe exception of a desktop next gen DNA sequencer in year 3. Which would run at least \n$150K if we are bringing sequencing capability inhouse. \nI can provide a detailed invoice on years 2 and 3 after feedback from you on the year 1 \nproposal. Again, most of the expenses are front loaded in year 1. The only other really \nbig ticket item would be a sequencer in year 3 (--$150K to have our own sequencer) +1- a \nrobot. \nSo here's the breakdown for year 1. Jeffrey, this is essentially lays out what I want to do \nover the lifetime of my research career. This is why my % effort is 40%.: \nI. Sequencing: \nWGS from Illumina = $5000 \nAmbry exome: $1000 \nCGI genome: $5000 \nTotal = $11,000 \n2. Bioinformatics infrastructure: 3 servers + 6 analyses programs. I need to drill down \non these costs more, Jeffrey, but assuming $5-10K/server (let's say $10K/server or \n$30K total) and $3K/analyses platform (or $18K total). \nTotal = $48K. \n3. Adult stem cell, genomic engineering, and other cellular work: $15K for reagents \nonly; $60K X2 years for a postdoc personally working on your cells and reporting to \nyou on a regular basis. I don't want to promise anything this early on, Jeffrey, but it \nseems reasonable to me that our analysis of your data and work on your cells would \nbe something that wou\n... [truncated, 2495 chars — for the full page use /api/corpus/document/EFTA01140225/11 or ?id=EFTA01140225&page=11]", "char_count": 2495}, {"efta_number": "EFTA01140225", "page_number": 12, "text_content": "Grand total for year 1 (excluding indirect costs) = $324K/yr \nCosts in year 2 should be less than $324K/yr \nCosts in year 3 go up if we add in our own sequencing capability (additional $150K-200K/yr) +/-\na robot. \nCost above does not include \"indirect costs\" from MGH, CHB, or HMS but I'm looking into \nways to avoid this being charged. We will need to cover space rental though for the servers and \nperhaps one study office and study exam room if possible. \nAs I discussed, the MGH Virtual Genomics Clinic study is happening regardless and the goal \nwould be that your initial funding would get us the initial data and publications to fund the \nproject indefinitely. It's possible that we're independent from your funding by Year 2. Or \nalternatively, we could continue receiving your funding in addition to other sources and step up \nour timeline. \nIf you wanted to make a larger up front investment (eg take care of years 1-3), we could step \nthings up so that inhouse sequencing (with access for you, underinsured MGH patients, and \nanyone of your choosing (eg, family/friends who are willing to participate)) is available through \nThakuria lab at MGH by Fall/Winter of this year. The in vivo animal model studies on zebrafish \ncould also begin in year 1 (for --$15K investment) rather than in year 2. (ie, this would be \nintroducing mutation(s) found in our subjects into zebrafish and observing as well as correcting \nthe mutation in a live organism.) \nI'm going to end here. Let me know what you think. With the invoice above, you can imagine a \nstripped down version covering only the work on your samples. (eg, no onsite servers, no \npersonnel other than my own effort, minimal analyses tools) With the invoice though, you should \nget a sense for what gets affected with every cut (including delays in our timeline). \nJeffrey, thanks for your valuable time and willingness to hear this proposal. I'm feeling guilty \nabout writing such a long proposal but hopefully some of these details are \n... [truncated, 2651 chars — for the full page use /api/corpus/document/EFTA01140225/12 or ?id=EFTA01140225&page=12]", "char_count": 2651}, {"efta_number": "EFTA01140225", "page_number": 13, "text_content": "http://www.massgeneral.org/doctors/doctor.aspx?id=18287 \n(I need to spend a little time adding my pic and other info to it to jazz it up sometime soon. I'm \nalso due to be upgraded 2 notches from instructor to associate professor at HMS and MGH. I've \nmet all the requirements - I just need to complete and submit some paperwork.) \nAnd here's one of my hms profiles with a partial listing of my publications: \nhttp://connects.catalyst.harvard.edu/Profiles/display/Person/8411 \nBeing an internal news (rather than scientific) publication, this shouldn't carry a lot of weight but \nI was also in this piece in the last issue of Harvard Med magazine. (see attached pdf) So, this \ngives you an idea of how timely this type of work is. \nI've also attached my NIH biosketch for your reference. \nLastly, my first author publication, Back to the Future: From Genome to Metabolome, gives you \nan idea of the type of individualized analyses we could do on the biochemical side using an \nindividual's genomic data to guide us. Potentially leading to customized diets in the future. \nThanks again, Jeffrey. Look forward to hearing from you after you've h \n' w the \nmaterial. Email or call my cell anytime with questions or clarifications \nSincerely, \nJoe Thakuria \nJoseph V. Thakuria, MD, MMSc \nMedical Genetics and Metabolism Attending Physician \nDirector, Stickler Syndrome Program \nMassachusetts General Hospital \nSimches Bldg. \n185 Cambridge St., Rm. 2222 \nBoston, MA 02114 \nEFTA01140238\n", "char_count": 1480}]}